# Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

> **NCT01568008** · — · COMPLETED · sponsor: **Allergan** · enrollment: 933 (actual)

## Conditions studied

- Open-Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Bimatoprost 0.01% ophthalmic solution

## Key facts

- **NCT ID:** NCT01568008
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 933 (ACTUAL)
- **Last updated:** 2013-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01568008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01568008, "Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01568008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*